ANN ARBOR, Mich., June 9, 2008 (PRIME NEWSWIRE) -- MIR Preclinical Services (MIR) has added preclinical models of atherosclerosis to its list of in vivo service offerings. These models are used to determine whether or not drug candidates have an effect on the development or regression of atherosclerosis in genetically engineered mouse models (GEMM’s) and to determine whether or not this effect is related to changes in plasma cholesterol levels. This research is vitally important since atherosclerosis is the leading cause of morbidity and mortality in the U.S. This very intense area of research for the pharmaceutical and biotechnology industry includes assessment of hypolipidemic and lipid regulating agents, thrombolytics and the application of thrombolytics to medical devices and novel anti-inflammatory strategies.
